Answers are grounded in this paper and cite their sources.
Type 1 diabetes (T1D) is defined by autoimmune β-cell destruction and absolute insulin deficiency, yet a substantial proportion of patients develop clinically relevant insulin resistance (IR) that elevates exogenous insulin requirements, glycemic variability, and cardiovascular risk. The molecular architecture of this IR phenotype remains incompletely mapped and may involve coordinated dysregulation across insulin signaling, lipid metabolism, innate immune activation, mitochondrial function, and tissue-level energy homeostasis. Here we present a fully bioinformatic integrative framework that interrogates publicly available peripheral blood mononuclear cell (PBMC) transcriptomes from individuals with T1D (GSE9006, GSE55098, GSE72377, GSE156035) together with a subcutaneous adipose reference signature of insulin resistance (GSE245948). The analytic pipeline comprises differential expression modeling (limma), weighted gene co-expression network analysis (WGCNA), gene-set variation and single-sample enrichment scoring (GSVA/ssGSEA), protein–protein interaction network construction (STRING/Cytoscape), functional enrichment (clusterProfiler/Enrichr), and supervised molecular feature selection (LASSO and random forest). Five a priori biological axes guide the investigation: (1) intracellular insulin signaling, (2) lipid metabolism and storage, (3) metabolic inflammation and innate immunity, (4) mitochondrial dysfunction and oxidative stress, and (5) transcriptional correlates of hepatic and skeletal-muscle insulin action detectable in circulating cells. Candidate genes within each axis (INSR, IRS1, IRS2, PIK3CA, AKT2, SLC2A4, FOXO1, GSK3B, PPARGC1A, CD36, SREBF1, FASN, TNF, IL6, NFKB1, NLRP3, TFAM, NDUFS1, SOD2, NFE2L2 and related molecules) serve as investigation targets rather than presupposed results. Findings are interpreted strictly as systemic molecular signatures compatible with IR mechanisms, not as direct functional evidence of muscle or hepatic insulin resistance. Independent cross-dataset validation and explicit separation of leukocyte inflammatory programs from classical metabolic-tissue IR programs are enforced throughout. This open-source roadmap generates prioritized candidate pathways for experimental validation and advances a systems-level view of immunometabolic dysfunction in T1D.
No takes yet. Share an insight, caveat, or question.
Andrade et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: